Hydroxyalkyne–Bithiophene Derivatives: Synthesis and Antileishmanial Activity
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Rayanne Regina Beltrame Machado und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Inovação Tecnológica no Desenvolvimento de Fármacos e Cosméticos, Departamento de Ciências Básica da Saúde, Universidade Estadual de M…. Hauptthemen laut MEDLINE: Thiophenes, Antiprotozoal Agents, Leishmania, Alkynes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Araucária, Programa de Apoio ao Núcleo de Excelência (PRONEX), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Abstract (Originalsprache)
Leishmaniasis is one of the most important neglected tropical diseases, prevalent in underdeveloped or developing countries, and new pharmacological agents for this disease are urgently needed. In this study, thiophene derivatives based on the natural product 5′‐methyl‐(5‐[4‐acetoxy‐1‐butynyl])‐2,2′‐bithiophene were synthesized and evaluated against promastigote forms of Leishmania amazonensis . The bithiophene BT‐1 was the most potent and selective synthetic compound toward the parasites, exhibiting IC 50 of 23.2 μM against promastigotes and CC 50 of 216.5 μM against macrophages, and its mechanism of action was determined through biochemical and ultrastructural analyses. An accumulation of lipid bodies, loss of cellular content, increased reactive oxygen species production and lipid peroxidation, damage to the plasma membrane, and mitochondrial depolarization were observed in BT‐1 ‐treated parasites. The results indicated that the death of L. amazonensis induced by BT‐1 occurred via destabilizing the parasite's redox homeostasis. Our results also showed that the synthesis based on the natural compound scaffold consisted of useful strategies to obtain new synthetic antileishmanial compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Inovação Tecnológica no Desenvolvimento de Fármacos e Cosméticos, Departamento de Ciências Básica da Saúde, Universidade Estadual de Maringá (UEM), Maringá, Brazil.
- Programa de Pós-Graduação Em Química, Departamento de Química, Universidade Estadual de Maringá (UEM), Maringá, Brazil.
ORCID-Profile: Rayanne Regina Beltrame Machado, Carla Maria Beraldi Gomes, Sueli de Oliveira Silva, Maria Helena Sarragiotto, Danielle Lazarin-Bidóia
Förderung
- Fundação Araucária
- Programa de Apoio ao Núcleo de Excelência (PRONEX)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Capacitação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- Universidade Estadual de Maringá (UEM)
- Complexo de Centrais de Apoio à Pesquisa-UEM
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Machado, R. R. B., Salvador, D. L., Gomes, C. M. B., Bakoshi, A. B. K., Ueda-Nakamura, T., de Oliveira Silva, S., Nakamura, C. V., Sarragiotto, M. H., & Lazarin-Bidóia, D. (2025). Hydroxyalkyne–Bithiophene Derivatives: Synthesis and Antileishmanial Activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70167
Vancouver
Machado RRB, Salvador DL, Gomes CMB, Bakoshi ABK, Ueda-Nakamura T, de Oliveira Silva S, et al. Hydroxyalkyne–Bithiophene Derivatives: Synthesis and Antileishmanial Activity. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70167
BibTeX
@article{Machado2025,
author = {Machado, Rayanne Regina Beltrame and Salvador, Deysiane Lima and Gomes, Carla Maria Beraldi and Bakoshi, Amanda Beatriz Kawano and Ueda-Nakamura, Tânia and de Oliveira Silva, Sueli and Nakamura, Celso Vataru and Sarragiotto, Maria Helena and Lazarin-Bidóia, Danielle},
title = {Hydroxyalkyne–Bithiophene Derivatives: Synthesis and Antileishmanial Activity},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70167}
}
EUVIMED